Screener
Carlsmed, Inc. CARL Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Carlsmed, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Carlsmed, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001794546-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Payments for deferred initial public offering costs | — | (2,648) |
| Proceeds from issuance of Series C convertible preferred stock, net of issuance costs | — | 11,919 |
| Proceeds from exercises of stock options | 472 | 183 |
| Proceeds from employee stock plan purchases | 207 | — |
| Net cash provided by financing activities | 679 | 9,454 |
| (Decrease) increase in cash, cash equivalents, and restricted cash | (39,549) | (6,653) |
| Cash, cash equivalents, and restricted cash at beginning of the period | 85,893 | 40,225 |
| Cash, cash equivalents, and restricted cash at end of the period | $46,344 | $33,572 |
Item 1. Financial Statements.
FAQ
- What is Carlsmed, Inc.'s financing cash flow?
- Carlsmed, Inc. (CARL) reported financing cash flow of $243K in Q2 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Carlsmed, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude